Northwire Canada EditionMonday, July 13, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
M&A / Property Routine +

WELL Health Partners with AliveCor to Bring AI-Powered Cardiac Monitoring and Cardiologist Oversight to Canadians

WELL · Price

Executive Summary

  • WELL Health Technologies Corp. announced a strategic partnership with AliveCor to provide cardiologist‑reviewed ECG interpretation services through the Kardia platform for Canadian patients.
  • The service integrates WELL’s network of Canadian‑registered cardiologists into AliveCor’s AI‑powered app, delivering clinician reviews within 24 hours and generating new clinical services revenue for WELL.
  • The partnership is positioned as the first phase, with future expansion possibilities including deployment of AliveCor’s Kardia 12L 12‑lead ECG system across WELL’s clinic network.

Key Details

  • Partnership Scope: Canadian‑registered cardiologists from WELL will review ECGs recorded on AliveCor’s Kardia devices; results are returned to patients within 24 hours.
  • Revenue Model: WELL is compensated per cardiologist review performed, creating a scalable clinical services revenue stream.
  • Clinical Benefit: Combines AI‑based arrhythmia detection (three common arrhythmias) with physician validation, aiming to reduce wait times for specialist cardiology appointments (average 15.3 weeks).
  • Future Phases: Potential rollout of AliveCor’s Kardia 12L pocket‑sized 12‑lead ECG system in WELL’s primary care, urgent care, and outpatient settings.
  • Market Context: Canadian elective cardiology wait times increased by 53 % over the past year, highlighting demand for rapid remote cardiac assessment.
  • Quotes:
  • Dina Sergi, CEO of WELL Health Diagnostic Centres: “This partnership … creates a new, scalable clinical services revenue stream for WELL.”
  • Navneet Malpani, SVP of Partner Alliances at AliveCor: “We are providing our Canadian customers with an essential layer of clinical oversight… without having to wait for in‑person appointments.”

Notable Quotes

  • “By providing clinician review to AliveCor’s AI‑driven analysis, we are helping patients get answers faster, reducing pressure on the healthcare system, and creating a new, scalable clinical services revenue stream for WELL.” – Dina Sergi, CEO, WELL Health Diagnostic Centres
  • “Patients can receive expert guidance from a certified cardiologist when they need it most, without having to wait for in‑person appointments.” – Navneet Malpani, Senior Vice President of Partner Alliances, AliveCor
Read the original news release →

More from WELL HEALTH TECHNOLOGIES CORP. J